Cargando…

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma

Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marrugal, Ángela, Ferrer, Irene, Gómez-Sánchez, David, Quintanal-Villalonga, Álvaro, Pastor, María Dolores, Ojeda, Laura, Paz-Ares, Luis, Molina-Pinelo, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962034/ https://www.ncbi.nlm.nih.gov/pubmed/33802597 http://dx.doi.org/10.3390/ijms22052538

Ejemplares similares

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy
por: Marrugal, Ángela, et al.
Publicado: (2023)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry
por: Marrugal, Ángela, et al.
Publicado: (2019)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

Corrigendum to “Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer”
por: Marrugal, Ángela, et al.
Publicado: (2018)

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer
por: Marrugal, Ángela, et al.
Publicado: (2016)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
por: Ferrer, Irene, et al.
Publicado: (2018)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer
por: Verdugo-Sivianes, Eva M., et al.
Publicado: (2017)

Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage
por: Pastor, Maria Dolores, et al.
Publicado: (2013)

Association between the miRNA Signatures in Plasma and Bronchoalveolar Fluid in Respiratory Pathologies
por: Molina-Pinelo, Sonia, et al.
Publicado: (2012)

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2014)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2015)

Hsp90 Inhibition Decreases Mitochondrial Protein Turnover
por: Margineantu, Daciana H., et al.
Publicado: (2007)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

Plasma HSP90α and liver cancer: a potential biomarker?
por: Sourbier, Carole
Publicado: (2017)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

The Keap1 signaling in the regulation of HSP90 pathway
por: Bonura, Angela, et al.
Publicado: (2022)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
por: Lackie, Rachel E., et al.
Publicado: (2017)

Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2014)

Hsp40s Specify Functions of Hsp104 and Hsp90 Protein Chaperone Machines
por: Reidy, Michael, et al.
Publicado: (2014)

Transcriptomic and Proteomic Investigation of HSP90A as a Potential Biomarker for HCC
por: Zhou, Yi, et al.
Publicado: (2015)

Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
por: Murillo-Solano, Claribel, et al.
Publicado: (2017)

Analysis of serum Hsp90 as a potential biomarker of β cell autoimmunity in type 1 diabetes
por: Ocaña, Gail J., et al.
Publicado: (2019)

Control of Canalization and Evolvability by Hsp90
por: Milton, Claire C., et al.
Publicado: (2006)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2i32g56q3rgopv6dog1vufso8l